Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

Salvatore Minisola*, Fernando Marin, David L. Kendler, Piet Geusens, Cristiano A. F. Zerbini, Luis A. Russo, Enrique Casado, Astrid Fahrleitner-Pammer, Jan J. Stepan, Eric Lespessailles, Ruediger Moericke, Alicia Bagur, Peter Lakatos, Pedro Lopez-Romero, Jean Jacques Body

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number10
Number of pages8
JournalArchives of Osteoporosis
Volume14
Issue number1
DOIs
Publication statusPublished - 18 Jan 2019

Keywords

  • Teriparatide
  • Fractures
  • Postmenopausal osteoporosis
  • 25-Hydroxy-vitamin D
  • Subgroup analysis
  • Bisphosphonates
  • BONE-MINERAL DENSITY
  • VITAMIN-D DEFICIENCY
  • POSTMENOPAUSAL WOMEN
  • 25-HYDROXYVITAMIN-D
  • OSTEOPOROSIS
  • ASSOCIATION
  • HIP

Cite this

Minisola, S., Marin, F., Kendler, D. L., Geusens, P., Zerbini, C. A. F., Russo, L. A., Casado, E., Fahrleitner-Pammer, A., Stepan, J. J., Lespessailles, E., Moericke, R., Bagur, A., Lakatos, P., Lopez-Romero, P., & Body, J. J. (2019). Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Archives of Osteoporosis, 14(1), [10]. https://doi.org/10.1007/s11657-019-0561-x